Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival
- PMID: 12445060
- DOI: 10.1046/j.1365-2168.2002.02268.x
Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival
Abstract
Background: The results of surgical treatment for intrahepatic cholangiocarcinoma (ICC) and specific factors influencing survival are still unclear.
Methods: Between 1984 and 2001, 62 patients with ICC underwent laparotomy, with a 77 per cent (48 patients) resectability rate. The tumours in these 48 patients were reviewed retrospectively to examine the relationship between gross appearance (mass forming, periductal infiltrating, intraductal growth, and mass forming plus periductal infiltrating) and patient survival, as well as the manner of recurrence. In patients with mass-forming and mass-forming plus periductal infiltrating types, univariate and multivariate analyses of potential prognostic factors were performed.
Results: The 1-, 3- and 5-year survival rates were 62, 38 and 23 per cent respectively. All patients with the intraductal growth type remained alive after intervals ranging from 8 to 72 months. Univariate analysis showed multiple hepatic lesions, liver capsule invasion, presence of cancer cells in the resection margin, and high serum carbohydrate antigen (CA) 19-9 level to be significant negative prognostic factors. Lymph node involvement, however, was not identified as a significant prognostic factor. With multivariate analysis, multiple hepatic lesions and high serum CA19-9 concentration were found to be significantly related to prognosis. The most frequent recurrence site was the remnant liver.
Conclusion: These results suggest that the intraductal growth type of tumour should be treated as a distinct entity compared with other types of ICC. Multiple tumours and high serum CA19-9 level were signs of dismal prognosis, whereas not all patients with lymph node involvement had a poor prognosis.
Similar articles
-
Macroscopic types of intrahepatic cholangiocarcinoma: clinicopathologic features and surgical outcomes.Hepatogastroenterology. 2002 Mar-Apr;49(44):326-9. Hepatogastroenterology. 2002. PMID: 11995443
-
Surgical treatment of mass-forming intrahepatic cholangiocarcinoma: an 11-year Western single-center experience in 107 patients.Ann Surg Oncol. 2009 Feb;16(2):404-12. doi: 10.1245/s10434-008-0227-1. Epub 2008 Nov 27. Ann Surg Oncol. 2009. PMID: 19037702 Clinical Trial.
-
An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma.Br J Surg. 2004 Jan;91(1):99-104. doi: 10.1002/bjs.4366. Br J Surg. 2004. PMID: 14716802
-
[Intrahepatic bile duct carcinoma (cholangiocarcinoma)].Nihon Geka Gakkai Zasshi. 1997 May;98(5):484-90. Nihon Geka Gakkai Zasshi. 1997. PMID: 9213313 Review. Japanese.
-
Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature.Liver Transpl. 2001 Dec;7(12):1023-33. doi: 10.1053/jlts.2001.29419. Liver Transpl. 2001. PMID: 11753904 Review.
Cited by
-
Periductal infiltrating type of intrahepatic cholangiocarcinoma: a rare macroscopic type without any apparent mass.Surg Today. 2012 Dec;42(12):1189-94. doi: 10.1007/s00595-012-0145-5. Epub 2012 Feb 21. Surg Today. 2012. PMID: 22350300
-
Nonanatomic resection is not inferior to anatomic resection for primary intrahepatic cholangiocarcinoma: A propensity score analysis.Sci Rep. 2018 Dec 12;8(1):17799. doi: 10.1038/s41598-018-35911-5. Sci Rep. 2018. PMID: 30542113 Free PMC article.
-
Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review.J Gastrointest Oncol. 2015 Oct;6(5):570-88. doi: 10.3978/j.issn.2078-6891.2015.055. J Gastrointest Oncol. 2015. PMID: 26487951 Free PMC article. Review.
-
Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma.Cancer Gene Ther. 2015 Dec;22(12):591-6. doi: 10.1038/cgt.2015.60. Epub 2015 Nov 20. Cancer Gene Ther. 2015. PMID: 26584530
-
STAT3 overexpression promotes metastasis in intrahepatic cholangiocarcinoma and correlates negatively with surgical outcome.Oncotarget. 2017 Jan 31;8(5):7710-7721. doi: 10.18632/oncotarget.13846. Oncotarget. 2017. PMID: 28032598 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical